Search Result

Results for "

HBsAg

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (3) Bacterial (1) Bcl-2 Family (2) Caspase (2) CDK (2) DNA/RNA Synthesis (1) Fungal (1) FXR (1) HBV (58) HIV (2) IFNAR (1) Influenza Virus (2) JNK (2) NOD-like Receptor (NLR) (2) PI3K (2) PKC (2) Potassium Channel (1) Reference Standards (1) Small Interfering RNA (siRNA) (2) STING (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (5) Infection (58) Inflammation/Immunology (6) Neurological Disease (3)
Oligonucleotides:	siRNA drugs (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117650A

RG7834 Maximum Cited Publications 9 Publications Verification RO 7020322; (S)-RO0321	HBV	Infection
RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells .

HY-109197

Vonafexor 2 Publications Verification EYP001	FXR HBV	Infection
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .

HY-N0699

Daphnoretin 3 Publications Verification Dephnoretin; Thymelol	PKC Influenza Virus NOD-like Receptor (NLR) Apoptosis HBV JNK PI3K Akt CDK Caspase Bcl-2 Family	Infection Inflammation/Immunology Cancer
Daphnoretin (Dephnoretin; Thymelol) is a protein kinase C (PKC) activator that inhibits the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and exhibits antiviral activity. Daphnoretin exerts its antitumor effects by inhibiting the activation of the PI3K/AKT signaling pathway and triggers the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and activation of the NLRP3 inflammasome. Daphnoretin regulates the differentiation and maturation of dendritic cells, inhibits their immunostimulatory function by downregulating the phosphorylation level of JNK, and thus exerts a protective effect in skin graft rejection .

HY-P990015

Tobevibart VIR-3434	HBV	Infection
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .

HY-177022

ALG-001075	HBV	Infection
ALG-001075, a capsid assembly modulator (CAM), is an orally active HBV inhibitor. ALG-001075 effectively blocks not only HBV DNA production but also extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. ALG-001075 shows pronounced reductions of circulating HBV DNA in the AAV-HBV mouse model. ALG-001075 can be used for the study of Chronic hepatitis B (CHB) .

HY-148348

AB-836	HBV	Infection
AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein. AB-836 can be used in research related to chronic hepatitis B .

HY-157993

SAG-524	HBV	Infection
SAG-524 is a potent oral small molecule HBV viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC₅₀ 0.92 and 1.4 nM, respectively .

HY-148560A

trans-ccc_R08	HBV DNA/RNA Synthesis	Infection
trans-ccc_R08 (Compound 1-B) is a cccDNA inhibitor with anti-HBV activity, with an IC₅₀ of 0.14 μM for HBeAg and an IC₅₀ of 0.08 μM for HBsAg in in vitro assays. trans-ccc_R08 inhibits covalently closed circular DNA (cccDNA). trans-ccc_R08 is applicable to research related to hepatitis B virus infection .

HY-P99693

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .

HY-147266

Elebsiran sodium VIR-2218 sodium	Small Interfering RNA (siRNA) HBV	Infection
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

HY-133721

Chamaechromone	HBV	Infection Inflammation/Immunology
Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-N4168

3-O-Caffeoylquinic acid methyl ester	HBV	Infection Cancer
3-O-Caffeoylquinic acid methyl ester is a monocaffeoylquinic acid derivative and phenolic acid component, which can be found in the whole plant of Pyrrosia calvata (Backer) Ching and the flower buds of Lonicera japonica Thunb .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-123336

Schisantherin C	HBV	Infection
Schisantherin C exhibits anti-HBV activity with potency against HBsAg and HBeAg secretion by 59.7% and 34.7% at 50μg/mL .

HY-147266A

Elebsiran VIR-2218	HBV Small Interfering RNA (siRNA)	Infection
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections .

HY-148783

HBV-IN-32	HBV	Infection
HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC₅₀ value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth .

HY-P99608

Exbivirumab	HBV	Infection
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .

HY-N8107

Matairesinol monoglucoside 2 Publications Verification	STING IFNAR HBV	Infection
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection .

HY-126970

HBF-0259	HBV	Infection
HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC₅₀ of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .

HY-155547

HBV-IN-34	HBV	Infection
HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC₅₀ of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively .

HY-P2783

Destruxin B2	HBV	Infection
Destruxin B2 (compound 5) is a natural depsipeptide that can be inhibits hepatitis B surface antigen (HBsAg) secretion in Hep3B cells with an IC₅₀ 1.30 μM .

HY-N3093

Periglaucine B (+)-Periglaucine B	HBV	Infection
Periglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC₅₀ of 0.47 mM .

HY-145055

HBV-IN-11	HBV	Infection
HBV-IN-11 is a potent HBsAg secretion inhibitor with an EC₅₀ of 0.46 µM (From patent WO2018085619A1, example 28) .

HY-P4043

Hepatitis b virus pre-s region (120-145)	HBV	Infection Inflammation/Immunology
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg .

HY-145060

HBV-IN-13	HBV	Infection
HBV-IN-12 is a potent hepatitis B surface antigen *(HBsAg)* inhibitor. From patent WO2021204252A1, compound 1_B .

HY-P4045

HBV Seq2 aa:208-216	HBV	Infection
HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus .

HY-148782

HBV-IN-31	HBV	Infection
HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC₅₀ value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .

HY-145053

HBV-IN-10	HBV	Infection
HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen *(HBsAg)* inhibitor (0.001 μM< EC₅₀ ≤0.05 μM). From patent WO2021204258A1, compound 6 .

HY-N3094

Periglaucine A	HBV HIV	Infection
Periglaucine A, a hasubanane-type alkaloid, can be isolated from Pericampylus glaucus. Periglaucine A can inhibits HBV surface antigen (HBsAg) secretion in Hep G2.2.15 cells. Periglaucine A also shows anti-HIV-1 activity in C8166 cells (EC₅₀: 204 μM) .

HY-173278

AIC263282	HBV Potassium Channel	Infection
AIC263282 is a potent Hepatitis B Virus (HBV) capsid assembly modulator with an EC₅₀ of 3.8 nM. AIC263282 shows an IC₅₀ of 61 nM for hERG. AIC263282 exhibits activity against viral replication and hepatitis B surface antigen (HBsAG) on primary human hepatocytes .

HY-N2882

Apigenin-4'-α-L-rhamnoside	HBV	Infection
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of HBV. Apigenin-4'-α-L-rhamnoside inhibits the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells .

HY-145053A

(5S,8R)-HBV-IN-10	HBV	Infection
(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen *(HBsAg)* inhibitor (0.001 μM< EC₅₀ ≤0.05 μM). From patent WO2021204258A1, compound 6 .

HY-145059

HBV-IN-12	HBV	Infection
HBV-IN-12 is a potent hepatitis B surface antigen *(HBsAg)* inhibitor (0.001 μM< EC₅₀ ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC₅₀ ≤0.02 μM). From patent WO2021204252A1, compound 15 .

HY-147863

HBV-IN-24	HBV	Infection Neurological Disease
HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC₅₀ values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity .

HY-134635R

Dehydrozingerone (Standard)	Bacterial Fungal HIV	Infection Neurological Disease Cancer
Dehydrozingerone (Standard) is the analytical standard of Dehydrozingerone. This product is intended for research and analytical applications. Dehydrozingerone (Compound 10), a structural half analogue of Curcumin (HY-N0005), is a phenolic compound with antibacterial, anticancer, antioxidant, anti-Alzheimer’s and antifungal activity, which is isolated from ginger (Zingiber officinale) rhizomes. Dehydrozingerone shows moderate inhibitory activities on the secretion of HBsAg in HepG 2 cells with an IC50 value of 0.50 mM .

HY-162579

TLR7 agonist 22	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC₅₀ value of 25.86 μM. TLR7 agonist 22 inhibits the cellular *HBsAg* secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents .

HY-159987

AB-161	HBV	Infection
AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC₅₀ value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research .

HY-P4044

HBV Seq2 aa:28-39	HBV	Infection
HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .

HY-171181

ZINC20451377	HBV	Infection
ZINC20451377 is a small molecule targeting hepatitis B (HBV) surface antigen (HBsAg) and can effectively inhibit wild-type hepatitis B and tenofovir (HY-13910)-resistant hepatitis B .

HY-161327

HBV-IN-44	HBV	Infection
HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC₅₀ value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro .

HY-N15419

Acutumidine	HBV	Infection
Acutumidine (compound 4) is an alkaloid with anti-HBV activity that can be isolated from Hypserpa nitida Miers. Acutumidine inhibits the production of *HBsAg* in Hep G2.2.15 cells stably transfected with HBV genome with an IC₅₀ value of 2.023 mM .

HY-W754691

Glaziovine	HBV	Infection
Glaziovine is an antiviral agent found in Hypserpa nitida. Glaziovine exhibits significant inhibitory activity against HBV, capable of suppressing hepatitis B virus surface antigen (HBsAg) secretion in Hep G2.2.15 cells transfected with HBV, with an IC₅₀ of 8 nM .

HY-148201

Oleana-2,12-dien-28-oic acid	HBV	Infection
Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, *HBsAg* and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research .

HY-145052

HBV-IN-9	HBV	Infection
HBV-IN-9 is a potent *HBsAg* (HBV Surface antigen) inhibitor (IC₅₀=10 nM) and HBV DNA production inhibitor (IC₅₀=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.

HY-170605

BA-AZT1	HBV	Infection
BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC₅₀ of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC₅₀ of 0.70 µM .

HY-145713

GS-8873 HBV-IN-19	HBV	Infection
GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC₅₀ of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys .

HY-107315

Alisol F 24-acetate	HBV Apoptosis	Infection Cancer
Alisol F 24-acetate is a triterpene compound that can be isolated from the rhizomes of Alisma orientalis. Alisol F 24-acetate inhibits the secretion of HBV surface antigen *HBsAg* and HBeAg with IC₅₀ values of 7.7 µM and 5.1 µM. Alisol F 24-acetate has proapoptotic activity and can be used for cancer research .

HY-N11792

Pedunculosumoside F	HBV	Others
Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC₅₀ value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells .

Cat. No.	Product Name	Target	Research Area

HY-P2783

Destruxin B2	HBV	Infection
Destruxin B2 (compound 5) is a natural depsipeptide that can be inhibits hepatitis B surface antigen (HBsAg) secretion in Hep3B cells with an IC₅₀ 1.30 μM .

HY-P4043

Hepatitis b virus pre-s region (120-145)	HBV	Infection Inflammation/Immunology
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg .

HY-P5332

*Aβ1-14-εK-HBsAg3 Th* UB311 immunogen II	Peptides	Others
Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P4045

HBV Seq2 aa:208-216	HBV	Infection
HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus .

HY-P4044

HBV Seq2 aa:28-39	HBV	Infection
HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990015

Tobevibart VIR-3434	HBV	Infection
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .

HY-P99693

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-P99608

Exbivirumab	HBV	Infection
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .

Species:	Virus (2)
Tag:	His (2)
Source:	E. coli Cell-free (1) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702356

	Large envelope Protein, HBV-D (Cell-Free, His) Large envelope protein; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen	Virus	E. coli Cell-free
	The large envelope protein has two conformations: “external” (Le-HBsAg) and “internal” (Li-HBsAg). In its external state, it mediates viral attachment, initiates infection, determines species specificity, and promotes viral particle internalization via caveolin-mediated endocytosis. Large envelope Protein, HBV-D (Cell-Free, His) is the recombinant Virus-derived Large envelope protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

HY-P702559

	Large envelope Protein, HBV-C (P.pastoris, 180a.a, His) S; Large envelope protein; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen	Virus	P. pastoris
	The large envelope protein is crucial in its two conformations, "outside" (Le-HBsAg) and "inside" (Li-HBsAg). Externally, it binds the virus to cellular receptors, initiates infection, determines species specificity, and promotes viral particle internalization via caveolin-mediated endocytosis. Large envelope Protein, HBV-C (P.pastoris, 180a.a, His) is the recombinant Virus-derived Large envelope protein, expressed by P. pastoris , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (2)
Application:	ELISA (2)
Isotype:	IgM (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81076

	HBsAg Antibody (YA913) L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; S; HBsAg_HBVC5.	ELISA
	HBsAg Antibody (YA913) is a Mouse-derived and non-conjugated IgM monoclonal antibody, targeting to HBsAg.

HY-P81076A

	HBsAg Antibody (YA913)(PBS only) L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; S; HBsAg_HBVC5.	ELISA
	HBsAg Antibody (YA913) is a Mouse-derived and non-conjugated IgM monoclonal antibody, targeting to HBsAg.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-147266

Elebsiran sodium VIR-2218 sodium		siRNAs siRNA drugs
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HBsAg

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products